SEC Comment Letter 0000000000-24-001249 to Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc.
Date: Feb. 1, 2024 · CIK: 0001855485 · Accession: 0000000000-24-001249
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-276741
Letter
United States securities and exchange commission logo February 1, 2024 Allan J. Camaisa Chief Executive Officer Calidi Biotherapeutics, Inc. 4475 Executive Drive, Suite 200 San Diego, CA 92121 Re:Calidi Biotherapeutics, Inc. Registration Statement on Form S-1 Filed January 29, 2024 File No. 333-276741 Dear Allan J. Camaisa: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel B. Eng, Esq.
Show Raw Text
United States securities and exchange commission logo
February 1, 2024
Allan J. Camaisa
Chief Executive Officer
Calidi Biotherapeutics, Inc.
4475 Executive Drive, Suite 200
San Diego, CA 92121
Re:Calidi Biotherapeutics, Inc.
Registration Statement on Form S-1
Filed January 29, 2024
File No. 333-276741
Dear Allan J. Camaisa:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel B. Eng, Esq.